Scarica l'app Stockscreener
3.70
0.00%
0.00
Pre-mercato:
3.99
0.29
+7.84%
Precedente Chiudi:
$3.70
Aprire:
$3.58
Volume 24 ore:
435.96K
Relative Volume:
0.61
Capitalizzazione di mercato:
$199.57M
Reddito:
$2.81M
Utile/perdita netta:
$-97.34M
Rapporto P/E:
-2.3418
EPS:
-1.58
Flusso di cassa netto:
$-91.47M
1 W Prestazione:
-1.86%
1M Prestazione:
-11.06%
6M Prestazione:
-59.65%
1 anno Prestazione:
-61.46%
Intervallo 1D:
$3.36
$3.7998
Intervallo di 1 settimana:
$3.36
$3.91
Portata 52W:
$2.86
$13.70
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Nome
Fulcrum Therapeutics Inc
Settore
Industria
Telefono
617-651-8851
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Confronta FULC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
3.70 | 199.57M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Downgrade | Stifel | Buy → Hold |
| 2024-09-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-09-25 | Iniziato | Goldman | Neutral |
| 2023-08-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Aggiornamento | Stifel | Hold → Buy |
| 2023-05-04 | Downgrade | Goldman | Buy → Neutral |
| 2023-03-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Downgrade | Stifel | Buy → Hold |
| 2023-02-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Iniziato | Goldman | Buy |
| 2022-03-08 | Iniziato | Oppenheimer | Outperform |
| 2022-03-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2020-10-16 | Iniziato | Piper Sandler | Overweight |
| 2020-08-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-08-12 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Fulcrum Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FULCRUM THERAPEUTICS Earnings Results: $FULC Reports Quarterly Earnings - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 - The Manila Times
Fulcrum Therapeutics, Inc. SEC 10-K Report - TradingView
Fulcrum Therapeutics Reports Q4 and Full Year 2024 Financial Results and Updates on Pioneering SCD Trial - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth ... - The Bakersfield Californian
Can Fulcrum's Improved Financials and Sickle Cell Trial Progress Attract Biotech Investors? - StockTitan
Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 20 - GuruFocus.com
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday - Defense World
Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details. - ACCESS Newswire
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Down 7.3% in January - MarketBeat
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. Scheduled to Release Q4 and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET - The Manila Times
Rare Disease Pioneer Fulcrum Sets Stage for Major 2024 Financial Revelation - StockTitan
Fulcrum Therapeutics (FULC) Stock Price, News & Analysis - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement - Seeking Alpha
Fulcrum (FULC) Issues Strategic Employee Stock Options PackageKey Details Revealed - StockTitan
FULCFulcrum Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Rating of "Hold" by Brokerages - MarketBeat
Rare Disease Pioneer Fulcrum Takes Center Stage at Major Healthcare Conference - StockTitan
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Average PT from Brokerages - Defense World
Fulcrum Therapeutics Insider Ups Holding During Year - Yahoo Finance UK
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect - ACCESS Newswire
Fulcrum Therapeutics (NASDAQ:FULC) versus Syros Pharmaceuticals (NASDAQ:SYRS) Financial Analysis - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - ACCESS Newswire
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Acquires 97,565 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics Advances Pociredir for Sickle Cell Disease - TipRanks
Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33 - Defense World
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33 - MarketBeat
Suvretta Capital Management, LLC Acquires Additional Shares in F - GuruFocus.com
Geode Capital Management LLC Raises Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Barclays PLC Boosts Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Stifel Financial Corp Decreases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Update - MarketBeat
State Street Corp Increases Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
State Street Corp Boosts Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online
Fulcrum Therapeutics jumps amid takeover speculation - MSN
Fulcrum Therapeutics Receives Termination Notice from Sanofi Ending Collaboration Agreement for Losmapimod - Defense World
There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump - Simply Wall St
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from S&P Pharmaceuticals Select Industry Index - Marketscreener.com
Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago - Yahoo Finance
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33 - Defense World
Charles Schwab Investment Management Inc. Acquires 393,202 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Charles Schwab Investment Management Inc. Has $2.03 Million Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics Inc Azioni (FULC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):